BeyondSpring (BYSI) Revenue (2020 - 2021)
BeyondSpring's (BYSI) quarterly Revenue came in at $338000.0 in Q4 2021, up 87.78% year-over-year from $180000.0 in Q4 2020, and little changed quarter-over-quarter from $337000.0 in Q3 2021.
Powered by 
Analysis
BeyondSpring (BYSI) Revenue (2020 - 2021) Analysis & Trends
BeyondSpring has disclosed Revenue across 2 years of filings, most recently posting $338000.0 for Q4 2021.
- In Q4 2021, Revenue rose 87.78% year-over-year to $338000.0; the TTM figure through Sep 2024 stood at $338000.0 (changed N/A YoY), while the FY2022 annual figure was $1.4 million, changed 0.0% from the prior year.
- Revenue came in at $338000.0 for Q4 2021 at BeyondSpring, roughly flat from $337000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $338000.0 in Q1 2021 to a low of $180000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 640.90 Bn | 620.14 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 449.82 Bn | 443.25 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 357.24 Bn | 350.10 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 267.03 Bn | 259.34 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Pfizer | 157.09 Bn | 145.39 Bn | 10.94 Bn | 15.03 Bn |
| 6 | Sanofi | 52.17 Bn | 44.78 Bn | 10.79 Bn | 13.48 Bn |
| 7 | Revolution Medicines | 42.83 Bn | 42.83 Bn | - | - |
| 8 | Incyte | 24.76 Bn | 20.23 Bn | 1.57 Bn | 1.67 Bn |
| 9 | United Therapeutics | 21.40 Bn | 18.73 Bn | 683.80 Mn | 783.30 Mn |
| 10 | BeyondSpring | 31.45 Mn | 31.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 338,000.00 |
| Sep 30, 2021 | 337,000.00 |
| Jun 30, 2021 | 338,000.00 |
| Mar 31, 2021 | 338,000.00 |
| Dec 31, 2020 | 180,000.00 |